Shruti Chaturvedi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/876654/publications.pdf

Version: 2024-02-01

77	2,039	279487 23	264894 42
papers	citations	h-index	g-index

77	77	77	3003
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Patient Treated with Infliximab for Chronic Uveitis. Ocular Immunology and Inflammation, 2022, 30, 241-243.	1.0	3
2	Complement dysregulation is associated with severe COVID-19 illness. Haematologica, 2022, 107, 1095-1105.	1.7	34
3	Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission. Blood Advances, 2022, 6, 1264-1270.	2.5	20
4	A 15â€year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism. American Journal of Hematology, 2022, 97, .	2.0	6
5	Eculizumab for refractory thrombosis in antiphospholipid syndrome. Blood Advances, 2022, 6, 1271-1277.	2.5	9
6	Reduced sensitivity of <scp>PLASMIC</scp> and <scp>French</scp> scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals. Transfusion, 2021, 61, 266-273.	0.8	24
7	Concurrent Hereditary Hemorrhagic Telangiectasia and Hereditary Hemochromatosis: A Case Report. American Journal of Medicine, 2021, 134, e205-e206.	0.6	0
8	Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. Journal of Thrombosis and Haemostasis, 2021, 19, 607-616.	1.9	45
9	Counting the cost of caplacizumab. Blood, 2021, 137, 871-872.	0.6	13
10	Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Advances, 2021, 5, 1504-1512.	2.5	13
11	COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria. Blood, 2021, 137, 3670-3673.	0.6	37
12	Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms. Cancers, 2021, 13, 3246.	1.7	5
13	Continuous-infusion von Willebrand factor concentrate is effective for the management of acquired von Willebrand disease. Blood Advances, 2021, 5, 2813-2816.	2.5	5
14	Major adverse cardiovascular events in survivors of immuneâ€mediated thrombotic thrombocytopenic purpura. American Journal of Hematology, 2021, 96, 1587-1594.	2.0	9
15	Updates on thrombotic thrombocytopenic purpura: Recent developments in pathogenesis, treatment and survivorship. Thrombosis Update, 2021, 5, 100062.	0.4	5
16	Complement Activation Drives Progression of Pre-Eclampsia to HELLP Syndrome. Blood, 2021, 138, 772-772.	0.6	0
17	Abundance of B Cell Receptors Harboring Elongated Polytyrosine and Polyserine Rich Motifs within Their Heavy Chain CDR3 Distinguishes Catastrophic and Antiphospholipid Syndrome. Blood, 2021, 138, 2117-2117.	0.6	1
18	Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors. Blood, 2021, 138, 3039-3039.	0.6	0

#	Article	IF	Citations
19	How to recognize and manage COVID-19-associated coagulopathy. Hematology American Society of Hematology Education Program, 2021, 2021, 614-620.	0.9	12
20	Outcomes of Cardiovascular Surgery Utilizing Heparin versus Direct Thrombin Inhibitors in Cardiopulmonary Bypass in Patients with Previously Diagnosed HIT. Thrombosis and Haemostasis, 2020, 120, 300-305.	1.8	4
21	Aspirin in ET: will twice a day keep thrombosis away?. Blood, 2020, 136, 151-153.	0.6	1
22	Ex vivo assays to detect complement activation in complementopathies. Clinical Immunology, 2020, 221, 108616.	1.4	7
23	Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood, 2020, 136, 2080-2089.	0.6	283
24	Inflammation exerts a nonrandom risk in the acquisition and progression of the MPN: Insights from a Mendelian randomization study. EClinicalMedicine, 2020, 21, 100324.	3.2	2
25	Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature. Lupus, 2020, 29, 631-639.	0.8	13
26	A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway. Journal of Maternal-Fetal and Neonatal Medicine, 2020, , 1-9.	0.7	6
27	Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood, 2020, 135, 239-251.	0.6	145
28	Cardiovascular Disease Is a Leading Cause of Death in Thrombotic Thrombocytopenic Purpura (TTP) Survivors. Blood, 2020, 136, 22-23.	0.6	6
29	Eculizumab for Refractory Thrombosis in Antiphospholipid Syndrome. Blood, 2020, 136, 10-11.	0.6	2
30	O Complement, Where Aren't Thou. Advances in Chronic Kidney Disease, 2020, 27, 83-85.	0.6	1
31	Outcomes of a Clinician-Directed Protocol for Discontinuation of Complement Inhibition Therapy in Atypical Hemolytic Uremic Syndrome. Blood, 2020, 136, 24-25.	0.6	0
32	Defects in Sialic Acid Biosynthesis Cause Dysregulation of the Alternative Pathway of Complement. Blood, 2020, 136, 3-3.	0.6	0
33	How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns. Blood, 2019, 134, 415-420.	0.6	33
34	Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood, 2019, 134, 1037-1045.	0.6	58
35	Complement in the Pathophysiology of the Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 449.	2.2	87
36	Thromboelastography Parameters Are Associated with Cirrhosis Severity. Digestive Diseases and Sciences, 2019, 64, 2661-2670.	1.1	19

#	Article	IF	Citations
37	Different strokes for older folks (with TTP). Blood, 2019, 134, 2125-2126.	0.6	1
38	Approaches to Bloodless Surgery for Oncology Patients. Hematology/Oncology Clinics of North America, 2019, 33, 857-871.	0.9	6
39	Epidemiology and Clinical Manifestations of Immune Thrombocytopenia. Hamostaseologie, 2019, 39, 238-249.	0.9	40
40	Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis. Blood, 2019, 133, 615-617.	0.6	71
41	Preoperative treatment of anemia and outcomes in surgical Jehovah's Witness patients. American Journal of Hematology, 2019, 94, E55-E58.	2.0	8
42	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. Blood, 2019, 134, 90-90.	0.6	2
43	Anti-Mullerian Hormone, a Measure of Ovarian Reserve, Is Low in Female Subjects in the Multi-Center Study of Hydroxyurea. Blood, 2019, 134, 890-890.	0.6	1
44	Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic. Blood, 2019, 134, 4-4.	0.6	6
45	Splenectomy for immune thrombocytopenia: down but not out. Blood, 2018, 131, 1172-1182.	0.6	139
46	Extracellular Vesicles in the Antiphospholipid Syndrome. Seminars in Thrombosis and Hemostasis, 2018, 44, 493-504.	1.5	22
47	Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight, 2018, 3, .	2.3	65
48	Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura. Hematology American Society of Hematology Education Program, 2018, 2018, 539-547.	0.9	41
49	Clustering of endâ€organ disease and earlier mortality in adults with sickle cell disease: A retrospectiveâ€prospective cohort study. American Journal of Hematology, 2018, 93, 1153-1160.	2.0	30
50	Characteristics and outcomes of venous thromboembolism in patients with hereditary hemorrhagic telangiectasia. Thrombosis Research, 2018, 169, 41-43.	0.8	7
51	Risk Factors for Pregnancy-Associated Venous Thromboembolism: The Role of Maternal Age, Obesity, Smoking and Other Modifiable Risk Factors. Blood, 2018, 132, 3804-3804.	0.6	1
52	Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. Thrombosis Research, 2017, 151, 51-56.	0.8	32
53	Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: A cross-sectional survey. Thrombosis Research, 2017, 153, 14-18.	0.8	16
54	Elevated tricuspid regurgitant jet velocity, reduced forced expiratory volume in 1 second, and mortality in adults with sickle cell disease. American Journal of Hematology, 2017, 92, 125-130.	2.0	22

#	Article	IF	Citations
55	Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia. Pediatric Blood and Cancer, 2017, 64, e26401.	0.8	12
56	Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers. Current Rheumatology Reports, 2017, 19, 43.	2.1	11
57	Diagnosis and management of the antiphospholipid syndrome. Blood Reviews, 2017, 31, 406-417.	2.8	120
58	Renal Medullary Carcinoma: Establishing Standards in Practice. Journal of Oncology Practice, 2017, 13, 414-421.	2.5	52
59	Genome-wide association study to identify variants associated with acute severe vaso-occlusive pain in sickle cell anemia. Blood, 2017, 130, 686-688.	0.6	19
60	Treatment of chronic immune thrombocytopenia in children with romiplostim. Lancet, The, 2016, 388, 4-6.	6.3	3
61	Blind men and the refractory ITP elephant. Blood, 2016, 128, 1537-1538.	0.6	3
62	Evolution of sickle cell disease from a lifeâ€threatening disease of children to a chronic disease of adults: The last 40 years. American Journal of Hematology, 2016, 91, 5-14.	2.0	126
63	Rapidly progressive acute chest syndrome in individuals with sickle cell anemia: a distinct acute chest syndrome phenotype. American Journal of Hematology, 2016, 91, 1185-1190.	2.0	38
64	Increased morbidity during longâ€term followâ€up of survivors of thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, E208.	2.0	21
65	Over-testing for heparin induced thrombocytopenia in hospitalized patients. Journal of Thrombosis and Thrombolysis, 2015, 40, 12-16.	1.0	20
66	The antiphospholipid syndrome: still an enigma. Hematology American Society of Hematology Education Program, 2015, 2015, 53-60.	0.9	43
67	Circulating microparticles in patients with antiphospholipid antibodies: Characterization and associations. Thrombosis Research, 2015, 135, 102-108.	0.8	38
68	Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated with Mortality in Patients with Prostate Cancer. PLoS ONE, 2014, 9, e94048.	1.1	36
69	Recent advances in the antiphospholipid antibody syndrome. Current Opinion in Hematology, 2014, 21, 371-379.	1.2	22
70	Novel agents in the management of castration resistant prostate cancer. Journal of Carcinogenesis, 2014, 13, 5.	2.5	20
71	Management and outcomes for patients with TTP: analysis of 100 cases at a single institution. American Journal of Hematology, 2013, 88, 560-565.	2.0	28
72	Acral gangrene as a presentation of non-uremic calciphylaxis. Avicenna Journal of Medicine, 2013, 3, 109.	0.3	6

#	Article	IF	Citations
73	Thirteen Year Retrospective Analysis Of Adult Patients With Autoimmune Hemolytic Anemia At The Cleveland Clinic: Diagnosis and Prevalence Of Associated Disorders. Blood, 2013, 122, 955-955.	0.6	1
74	Detectable Or Normal ADAMTS13 Activity In Patients Presenting With Thrombotic Thrombocytopenic Purpura (TTP) Is Associated With Poor Renal Outcomes. Blood, 2013, 122, 4752-4752.	0.6	1
75	Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer. Blood, 2013, 122, 3626-3626.	0.6	0
76	Thirteen Year Retrospective Analysis Of Adult Patients With Autoimmune Hemolytic Anemia At The Cleveland Clinic: Responses To Therapy. Blood, 2013, 122, 3423-3423.	0.6	0
77	Thrombotic Thrombocytopenic Purpura At the Cleveland Clinic 2000â€“2012: Review of 100 Cases and Identification of Prognostic Factors. Blood, 2012, 120, 3325-3325.	0.6	1